Cypre, Inc.

San Francisco, CA · Founded 2016 · CIK 0001698684 · Biotech · Acquired

Human-derived 3D tumor models with high-resolution mechanism-of-action analytics platform

cypre.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$3.2M
2 Form D · Jan 2024
33 months since last filing
Contracts
—
No federal contracts on record
Patents
9
4 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,500,000
Private capital raisedForm D · SEC$1,684,554
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3316Zag Bio——
3317Actinium Pharmaceuticals, Inc.—$3.3M
3318ImmunoGen——
3319Cypre, Inc.—$3.2M
3320Optimeos Life Sciences, Inc.—$3.3M
3321Applied Proteomics, Inc.—$50M
3322DNA SEQ 2, INC.—$1.2M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Ellen ChangDirector · Executive Officer
  • Kolin HribarDirector · Executive Officer

Patents

USPTO · 4 granted of 9

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.